Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
Subscribe To Our Newsletter & Stay Updated
